MedinCell Future Growth
Future criteria checks 6/6
MedinCell is forecast to grow earnings and revenue by 117.6% and 37.9% per annum respectively. EPS is expected to grow by 110.6% per annum. Return on equity is forecast to be 58.9% in 3 years.
Key information
117.6%
Earnings growth rate
110.59%
EPS growth rate
| Pharmaceuticals earnings growth | 16.7% |
| Revenue growth rate | 37.9% |
| Future return on equity | 58.92% |
| Analyst coverage | Low |
| Last updated | 27 Mar 2026 |
Recent future growth updates
Recent updates
MedinCell S.A.'s (EPA:MEDCL) 27% Cheaper Price Remains In Tune With Revenues
Dec 01
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
Jun 19Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
Dec 25MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 87 | 50 | 40 | 38 | 4 |
| 3/31/2027 | 42 | 7 | 8 | 10 | 5 |
| 3/31/2026 | 32 | -14 | -20 | -10 | 5 |
| 9/30/2025 | 32 | -20 | -19 | -17 | N/A |
| 6/30/2025 | 30 | -19 | -1 | 1 | N/A |
| 3/31/2025 | 28 | -18 | 18 | 19 | N/A |
| 12/31/2024 | 20 | -25 | 19 | 20 | N/A |
| 9/30/2024 | 13 | -31 | 20 | 21 | N/A |
| 6/30/2024 | 13 | -28 | 3 | 5 | N/A |
| 3/31/2024 | 12 | -25 | -13 | -12 | N/A |
| 12/31/2023 | 13 | -26 | -18 | -17 | N/A |
| 9/30/2023 | 14 | -26 | -24 | -23 | N/A |
| 6/30/2023 | 14 | -29 | -23 | -22 | N/A |
| 3/31/2023 | 14 | -32 | -22 | -21 | N/A |
| 12/31/2022 | 13 | -29 | -22 | -21 | N/A |
| 9/30/2022 | 12 | -27 | -22 | -20 | N/A |
| 6/30/2022 | 10 | -26 | -23 | -21 | N/A |
| 3/31/2022 | 8 | -25 | -23 | -21 | N/A |
| 12/31/2021 | 9 | -22 | -21 | -19 | N/A |
| 9/30/2021 | 9 | -20 | -18 | -17 | N/A |
| 6/30/2021 | 9 | -19 | -15 | -14 | N/A |
| 3/31/2021 | 8 | -19 | -13 | -12 | N/A |
| 12/31/2020 | 7 | -22 | -12 | -11 | N/A |
| 9/30/2020 | 5 | -26 | -11 | -10 | N/A |
| 6/30/2020 | 6 | -25 | -12 | -11 | N/A |
| 3/31/2020 | 6 | -24 | -13 | -13 | N/A |
| 12/31/2019 | 6 | -21 | -16 | -16 | N/A |
| 9/30/2019 | 6 | -19 | -19 | -19 | N/A |
| 6/30/2019 | 5 | -19 | N/A | -17 | N/A |
| 3/31/2019 | 4 | -20 | N/A | -16 | N/A |
| 12/31/2018 | 6 | -17 | N/A | -11 | N/A |
| 9/30/2018 | 7 | -15 | N/A | -7 | N/A |
| 6/30/2018 | 8 | -12 | N/A | -6 | N/A |
| 3/31/2018 | 8 | -10 | N/A | -5 | N/A |
| 3/31/2017 | 10 | -4 | N/A | -3 | N/A |
| 3/31/2016 | 9 | 1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDCL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: MEDCL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEDCL is expected to become profitable in the next 3 years.
Revenue vs Market: MEDCL's revenue (37.9% per year) is forecast to grow faster than the French market (5.5% per year).
High Growth Revenue: MEDCL's revenue (37.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEDCL's Return on Equity is forecast to be very high in 3 years time (58.9%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 12:12 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MedinCell S.A. is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Brian Balchin | Jefferies LLC |